Funding for this research was provided by:
Stichting A Sister's Hope (-)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (99999.001321/2013-07)
KWF Kankerbestrijding (-)
Top Institute Pharma (T3-502)
Text and Data Mining valid from 2019-08-07
Received: 28 January 2019
Accepted: 24 July 2019
First Online: 7 August 2019
Ethics approval and consent to participate
: The IKA trial was approved by the central ethics committee of the Netherlands Cancer Institute. Informed consent was obtained from all participating patients. The trial was performed in accordance with the Declaration of Helsinki. For this retrospective translational study, no additional consent was required according to Dutch legislation, since the use of anonymized archival pathology left-over material does not interfere with patient care. Tumor tissue was handled according to the Dutch code of conduct for responsible use of human tissue in the context of health research.
: The original trial was approved by the central ethics committee of the Netherlands Cancer Institute and informed consent was obtained from all the study participants. For this retrospectively retrospective translational study, no additional consent was required, according to Dutch legislation. AS described in already published papers using data from this trial, (Beelen, K et al Breast Cancer Research 2014).
: SCL is an advisory board member for AstraZeneca, Cergentis, Novartis, Roche, and Sanofi. SCL received institutional research support funding from Adienne, Amgen, AstraZeneca, Genentech, Roche, Sanofi, and Tesaro. MK is an advisory board member for BMS. MK receives institutional research support from BMS and Roche. The other authors declare that they have no competing interests.